Inventor · disambiguated record
Norbert Wild
Also filed as: WILD JR NORBERT C · WILD NORBERT
7 granted patents·35 pending applications·316 citations·filing 1994–2019
84Inventor score
Top patents by PatentIndex Score
42 records- 0195US5962806ANon-lethal projectile for delivering an electric shock to a living targetJAYCOR·Filed 1996·Granted Oct 5, 1999·242 cites·63 claims
- 0287US5625525APortable electromagnetic stun device and methodJAYCOR·Filed 1994·Granted Apr 29, 1997·61 cites·10 claims
- 0378US8058013B2Assessing risk of disease progression in rheumatoid arthritis patientsKARL JOHANN·Filed 2009·Granted Nov 15, 2011·9 cites·2 claims
- 0475US9518990B2Secernin-1 as a marker for cancerWILD NORBERT·Filed 2011·Granted Dec 13, 2016·4 cites·4 claims
- 0564US2013171135A1Method to identify a patient with an increased likelihood of responding to an anti-cancer therapyHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 0664US2013183300A1Method to identify a patient with an increased likelihood of responding to an anti-cancer therapyHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 0764US2013243758A1Method to identify a patient with an increased likelihood of responding to an anti-cancer therapyHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 0863US2013336960A1Method to identify a patient with an increased likelihood of responding to an anti-cancer therapyHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 0963US2014017231A1Method to identify a patient with an increased likelihood of responding to an anti-cancer therapyHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 1063US2014017232A1Method to identify a patient with an increased likelihood of responding to an anti-cancer therapyHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 1163US2013336959A1Method to identify a patient with an increased likelihood of responding to an anti-cancer therapyHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 1263US2014193397A1Method to identify a patient with an increased likelihood of responding to an anti-cancer therapyHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 1363US2014056874A1Method to identify a pateint with an increased likelihood of responding to an anti-cancer therapyGENENTECH INC·Filed 2013·Application pending·0 cites
- 1463US2014056875A1Method to identify a pateint with an increased likelihood of responding to an anti-cancer therapyGENENTECH INC·Filed 2013·Application pending·0 cites
- 1563US2013344059A1Method to identify a patient with an increased likelihood of responding to an anti-cancer therapyGENENTECH INC·Filed 2013·Application pending·0 cites
- 1663US2014023639A1Method to identify a patient with an increased likelihood of responding to an anti-cancer therapyGENENTECH INC·Filed 2013·Application pending·0 cites
- 1760US2015072355A1Flap endonuclease-1 as a marker for cancerROCHE DIAGNOSTICS OPERATIONS·Filed 2014·Application pending·0 cites
- 1858US2014056876A1Method to identify a pateint with an increased likelihood of responding to an anti-cancer therapyHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 1958US2014023640A1Method to identify a pateint with an increased likelihood of responding to an anti-cancer therapyHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 2057US2013344060A1Method to identify a patient with an increased likelihood of responding to an anti-cancer therapyHOFFMANN LA ROCHE·Filed 2013·Application pending·0 cites
- 2156US2016169895A1Flap endonuclease-1 as a marker for cancerROCHE DIAGNOSTICS OPERATIONS·Filed 2016·Application pending·0 cites
- 2256US2015192587A1Use of protein s100a12 as a marker for colorectal cancerROCHE DIAGNOSTICS OPERATIONS·Filed 2014·Application pending·0 cites
- 2355US2017115294A1Use of protein s100a12 as a marker for colorectal cancerROCHE DIAGNOSTICS OPERATIONS INC·Filed 2017·Application pending·0 cites
- 2452US7981693B2Combined measurement of anti-CCP and serum amyloid A to assess rheumatoid arthritisROCHE DIAGNOSTICS OPERATIONS·Filed 2006·Granted Jul 19, 2011·0 cites·5 claims
- 2552US2016109461A1Fen1 as a marker for chronic obstructive pulmonary disease (copd)ROCHE DIAGNOSTICS OPERATIONS·Filed 2015·Application pending·0 cites
- 2652US2014341893A1Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancerGENENTECH INC·Filed 2014·Application pending·0 cites
- 2751US2014004544A1Fen1 as a marker for chronic obstructive pulmonary disease (copd)KARL JOHANN·Filed 2013·Application pending·0 cites
- 2850US2009286328A1Use of protein s100a12 as a marker for colorectal cancerWILD NORBERT·Filed 2008·Application pending·0 cites
- 2950US2012157335A1Flap Endonuclease-1 As A Marker For CancerWILD NORBERT·Filed 2012·Application pending·0 cites
- 3049US8062907B2Method to assess the severity of rheumatoid arthritis by measuring anti-CCP and serum amyloid AWILD NORBERT·Filed 2011·Granted Nov 22, 2011·0 cites·3 claims
- 3148US2015126401A1Calprotectin and hemoglobin/haptoglobin complex from stool sample to assess colorectal cancerROCHE DIAGNOSTICS OPERATIONS·Filed 2015·Application pending·0 cites
- 3248US2015352204A1Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancerHOFFMANN LA ROCHE·Filed 2014·Application pending·0 cites
- 3343US2009075312A1Assessing colorectal cancer by measuring osteopontin and carcinoembryonic antigenWILD NORBERT·Filed 2008·Application pending·0 cites
- 3442US7846674B2Assessing rheumatoid arthritis by measuring anti-CCP and interleukin 6ROCHE DIAGNOSTICS OPERATIONS·Filed 2006·Granted Dec 7, 2010·0 cites·4 claims
- 3542US2010159479A1Timp-1 as a marker for colorectal cancerROLLINGER WOLFGANG·Filed 2009·Application pending·0 cites
- 3641US2011129860A1Calprotectin and hemoglobin/haptoglobin complex from stool sample to assess colorectal cancerKARL JOHANN·Filed 2010·Application pending·0 cites
- 3741US2007184498A1Protein RS15A as a marker for colorectal cancerTACKE MICHAEL·Filed 2006·Application pending·0 cites
- 3840US2007072237A1Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6WILD NORBERT·Filed 2006·Application pending·0 cites
- 3940US2006257951A1Use of protein spee as a marker for breast cancerPESTLIN GABRIELE·Filed 2006·Application pending·0 cites
- 4039US2019137523A1Method and means for detecting the level of total vegf-aHOFFMANN LA ROCHE·Filed 2019·Application pending·0 cites
- 4138US2002119497A1Binding assaysFiled 2001·Application pending·0 cites
- 4233US2010240068A1Marker panel for colorectal cancerKARL JOHANN·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Norbert Wild files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →